##semicolon##
Ursodeoxycholic acid, Metabolic syndrome, Insulin sensitivity, Glucose regulation, Lipid metabolism, Hepatic steatosis, Anti-inflammatory effects, Antioxidant properties, Cardiometabolic risk.##submission.citations##
Lakić, B., et al. (2024). Beneficial effects of ursodeoxycholic acid on metabolic syndrome: A comprehensive review. Journal of Clinical Medicine, 13(1), 4187796.
Tsuchida, T., et al. (2012). Ursodeoxycholic acid improves insulin sensitivity and hepatic steatosis in high-fat diet-fed KK-A(y) mice. Diabetes, 61(3), 619–628.
Rashidbeygi, E., et al. (2025). The effects of ursodeoxycholic acid on cardiometabolic risk factors: A systematic review and meta-analysis. BMC Cardiovascular Disorders, 25(1), 45.
Mahmoud, A. A., et al. (2014). Ursodeoxycholic acid ameliorates fructose-induced metabolic syndrome in rats. PLOS ONE, 9(9), e106993.
Simental-Mendía, L. E., et al. (2019). Impact of ursodeoxycholic acid on circulating lipid levels: A meta-analysis. Lipids in Health and Disease, 18(1), 12.
Mueller, M., et al. (2015). Ursodeoxycholic acid exerts farnesoid X receptor-dependent effects on cholesterol and bile acid metabolism in non-alcoholic fatty liver disease. Journal of Hepatology, 62(4), 1018–1026.
Nadinskaia, M., et al. (2021). Ursodeoxycholic acid as a means of preventing metabolic syndrome: A clinical perspective. World Journal of Gastroenterology, 27(10), 959–968.
Ji, L., et al. (2025). Berberine ursodeoxycholate for the treatment of type 2 diabetes: A randomized clinical trial. JAMA Network Open, 8(1), e2830820.